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Background: Before highly active antiretroviral therapy, cytomegalovirus (CMV) retinitis was 
a major threat to vision in individuals with HIV. We investigate whether ophthalmic screening 
of asymptomatic HIV patients still has value in the highly active antiretroviral therapy era and 
consider CD4 thresholds in line with the world literature and UK experience.
Methods: A retrospective chart review was conducted of all patients seen by the HIV 
 Ophthalmic Service of a UK university hospital both before (2007–2008) and after (2011–2012) 
introduction of a threshold of CD4 lower than 100 cells/mm3. Data collected included CMV and 
HIV RNA load, CD4 cell counts and CD4 percentage, CMV-immunoglobulin G status, ocular 
symptoms, and evidence of HIV-related ocular disease. 
Results: In total, 54 patients were referred to the HIV ophthalmic service. Three patients failed 
to attend, resulting in complete data for 51 patients (n=24 for 2007–2008; n=27 for 2011–2012). 
Seven patients had ophthalmic manifestations of their HIV; these cases had lower CD4 counts 
than those with normal examinations (median [interquartile range], 9 [7–80] versus 175 [44–394]; 
P=0.0039; Mann–Whitney test). Six cases had HIV retinopathy without sight loss; one case had 
sight-threatening CMV retinitis associated with a CD4 count of 6 cells/mm3. 
Conclusion: Before 2008, our practice was to screen all asymptomatic patients with CD4 
counts lower than 200 cells/mm3. Screening asymptomatic patients with CD4 counts below 
100 cells/mm3 was not associated with any missed or late-presenting cases of CMV retinitis 
in our HIV population. 
Keywords: cytomegalovirus retinitis, HIV, HAART
Introduction
Cytomegalovirus (CMV) retinitis is the most common ocular opportunistic infection 
in patients with AIDS,1,2 despite widespread availability of highly active antiretroviral 
therapy (HAART).3 HAART combines the use of three antiretroviral drugs, includ-
ing a protease inhibitor.4 Before the advent of HAART, the 4-year cumulative risk of 
developing CMV retinitis in patients with HIV was around 25%,5,6 whereas more recent 
estimates suggest it is now nearer 7%.6–8 At present, late diagnosis of HIV is the main 
reason for CMV retinitis in HIV-infected individuals. The pattern and incidence of 
HIV-related ophthalmic presentations has changed in the post-HAART era, with few 
studies reporting them.9 Bekele et al found that 39.7% of patients with a CD4+ cell 
count lower than 200 cells/mm3 had ocular manifestations of HIV/AIDS in Jimma, 
Ethiopia, compared with 20.9% in those with counts higher than 200 cells/mm3.9
CMV retinitis causes severe retinal damage with a major effect on vision (notably 
field loss) and with a high risk of recurrence and/or complications such as retinal 
detachment or immune recovery uveitis. Although a number of clinical phenotypes 
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occur, CMV retinitis typically induces a progressive whiten-
ing of the retina around the vessels, with hemorrhages and 
necrosis described as occurring in a “brushfire” pattern. This 
is often associated with a mild vitreous inflammation and 
can progress at the end stage to a rhegmatogenous retinal 
detachment, causing a dramatic visual decline. 
The presence of CMV retinitis is also predictive of 
disseminated CMV disease and high mortality and is sight-
threatening.1,2 A number of previous studies have indicated 
that HIV-associated CMV retinitis occurs more commonly 
in patients with absolute CD4 counts of 50 cells/mm3 or less 
at the time of diagnosis,5,6 although cases occurring at higher 
levels are also reported.4,7,10
Baseline CD4 cell count is, however, generally consid-
ered a critical parameter in assessing risk for CMV retinitis. 
The value of prophylactic ophthalmic screening in asymp-
tomatic patients with HIV is uncertain, although where 
screening is undertaken, the CD4 level usually directs it. 
Other ocular complications of HIV that may be observed in 
this population include HIV-associated retinopathy, ocular 
toxoplasmosis, immune-recovery uveitis, and progressive 
outer retinal necrosis. In this retrospective study, we pres-
ent the screening outcomes of patients referred from the 
HIV clinic for ophthalmic assessment for two time periods: 
before and after the reduction of our screening threshold 
for asymptomatic patients with HIV to fewer than 100 CD4 
cells/mm3. The primary aim of the study was to investigate 
whether ophthalmic screening of asymptomatic HIV patients 
has value in the United Kingdom in the HAART era, and if 
so, whether it can be targeted to particular at-risk groups.
Methods
study population
A retrospective chart review was conducted of all patients 
seen by the HIV Ophthalmic Service of the University 
Hospitals Birmingham National Health Service Founda-
tion Trust over the course of two periods: 2007–2008 and 
2011–2012. During the first period, the CD4 threshold for 
referral and review of asymptomatic patients was CD4 lower 
than 200 cells/mm3 . The results of the 2007 survey appeared 
to show no value in screening those with CD4 count greater 
than 100 cells/mm3, and this was therefore revised in line 
with local and international experience.5,11 In the second 
period, a new threshold of lower than 100 cells/mm3 was 
used, and the effect on the effectiveness of screening was 
assessed. Ophthalmic review included clinical history and 
full ophthalmic examination, including dilated funduscopy. 
All blood was processed at a single laboratory (Department 
of Clinical Immunology, University of Birmingham, United 
Kingdom). CD4 counts were measured using Becton Dick-
inson (BD) MultiTEST CD3 FITC/CD8 PE/CD45 PerCP/
CD4 APC reagent and BD FACSCanto four-color flow 
cytometry. TruCOUNT Tubes and simultaneous forward and 
side scatter were used to obtain percentages and calculate 
absolute CD4 counts.
Data collected included CMV viral load, CD4 cell 
count, CD4% (percentage of total lymphocytes that are CD4 
T-cells), HIV RNA load, CMV immunoglobulin G, ocular 
symptoms, and evidence of any HIV-related ocular disease. 
A retinal consultant with expertise in HIV (HP) confirmed 
all clinical assessments.
Data analysis
Frequencies, means and medians of demographics, and 
clinical and laboratory characteristics were calculated. Com-
parisons were done for patients referred during the two study 
periods. Categorical variables were tested with Fisher’s exact 
test. Continuous nonparametric variables were tested with 
the Mann–Whitney test, and parametric variables were tested 
with Student’s t-test. A P-value less than 0.05 was used to 
indicate statistical significance. Data analysis was performed 
using GraphPad Prism (version 5.00).
Results
In total, over the course of two periods, 54 patients were 
referred to the HIV Ophthalmic Service: 26 patients dur-
ing 2007–2008 and 28 patients during 2011–2012. Three 
patients failed to attend their ophthalmology reviews (two of 
26 for 2007–2008 and one of 28 for 2011–2012), resulting in 
complete data for 51 patients (Table 1). During both periods, 
the majority of referrals were male (71% versus 74%; not 
significant; Fisher’s exact test). The proportion of patients 
who were African or Afro-Caribbean increased during the 
second period (29% versus 60% [P=0.048] for African/Afro- 
Caribbean versus all other ethnicities; Fisher’s exact test).
Patients in the second study period had overall lower CD4 
counts (median, 253 versus 62; P=0.034; Mann–Whitney 
test), with higher HIV RNA copy numbers (median, 19,990 
versus 51; P=0.0079; Mann–Whitney test). However, there 
was no significant difference when the groups were com-
pared on the basis of identical screening criteria (ie, with 
the exclusion of the asymptomatic group of CD4 higher than 
100 cells/mm3 but lower than 200 cells/mm3 seen during 
the first, but not the second, study period). Rates of CMV 
immunoglobulin G positivity were similar in the two groups 
(75% and 78%; not significant; Fisher’s exact test).
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In terms of ocular disease, a total of seven of 51 patients 
had ophthalmic manifestations of their HIV (Table 2). This 
included three of 24 patients in 2007 and four of 27 patients 
in 2011. All cases were asymptomatic at time of ophthalmic 
screening. In most cases (six of seven), the ocular disease 
was HIV retinopathy and was visually nonsignificant. In one 
of seven cases, bilateral CMV retinitis was noted, which was 
treated with an induction course of intravenous ganciclovir 
followed by maintenance oral valganciclovir. Unfortunately, 
this patient did not adhere to any treatment after 6 months, 
and the patient suffered a severe recurrence of CMV retinitis 
and died 11 months later. This patient was the only one of 
the seven patients with ocular disease to have died during 
the follow-up period (up to 7 years for group 1 and up to 
3 years for group 2).
The CD4 count in those patients with HIV-associated 
ophthalmic disease was significantly lower than in those with 
normal examinations, with a median (interquartile range) 
of nine (7–80) versus 175 (44–394) (P=0.0039; Mann–
Whitney test). The median HIV count in those patients with 
HIV-associated ophthalmic disease was significantly higher 
than in those with normal examinations, with a median 
(interquartile range) of 987,151 (568,025–997,270) versus 
470 (40–36,852) (P=0.0019; Mann–Whitney test). The one 
case with CMV retinitis (representing 2% of all patients 
screened) had a CD4 count of 6 cells/mm3 (CD4% =3) at 
the time of screening. This was the lowest recorded CD4 
count in our series; the peripheral blood CMV DNA copy 
number in this patient was 1.5×104 copies/mm3. There were 
no “late referrals” of patients with HIV-associated ophthalmic 
disease, and in particular no other cases of HIV-associated 
CMV retinitis, presented to the ophthalmic service during 
these periods. No cases of immune recovery uveitis were 
seen in our cohort.
Discussion
As the CD4 T-lymphocyte is the primary target of HIV, the 
CD4 count is commonly used as a surrogate laboratory indi-
cator of the degree of immunocompromise and potential risk 
of opportunistic infections, including CMV retinitis. CMV 
retinitis is frequently diagnosed late because of the lack of 
visual symptoms. Before 2008, our practice was to screen all 
asymptomatic patients with CD4 counts lower than 200 cells/
mm3. Our review in 2007–2008 of the cohort of 24 patients 
Table 1 Comparison between patients screened during the two study periods 
Characteristic Screening period 1  
(2007–2008)
Screening period 2  
(2011–2012)
P-value
number of patients 24 27
sex, n (%) 1.00*
 Male 17 (71) 20 (74)
 Female 7 (29) 6 (26)
ethnicity, n (%) 0.048*
 Caucasian 13 (54) 9 (33)
 african/afro-Caribbean 7 (29) 16 (60)
 european 4 (17) 2 (7)
 asian 0 (0) 0 (0)
CD4 count (cell/mm3), n (%) 0.034**
 0–50 5 (19) 11 (40)
 51–100 3 (11.5) 7 (26)
 101–200 3 (11.5) 2 (7)
 200 13 (50) 7 (26)
 no result 2 (8) 0
 Median 253 62
CD4% 0.274**
 Median (interquartile range) 18.0 (8.8–26.1) 10 (4–22.0)
hiV rna, copies/mm3 0.0079**
 Median (interquartile range) 51 (40–7,891) 19,990 (188–627,525)
Cytomegalovirus immunoglobulin g (%) 1.00*
 Positive 18 (75) 21 (78)
 negative 6 (25) 6 (22)
Ophthalmic manifestations of hiV, n (%) 1.00*
Present 3 (13) 4 (15)
not present 21 (87) 23 (85)
Notes: *Fisher’s exact test of (1) male versus female, (2) african/afro-Caribbean versus all other ethnicities, (3) cytomegalovirus immunoglobulin g-positive versus 
immunoglobulin g-negative, and (4) ophthalmic manifestations of hiV present versus not present. **Mann–Whitney test.
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seen found only one patient with CMV retinitis; this patient 
had a CD4 count of 6 cells/mm3. In light of this, and supported 
by other studies worldwide, we modified our screening crite-
ria to include asymptomatic patients with CD4 counts lower 
than 100 mm/µL. This report shows that during a subsequent 
study period, the introduction of the new screening criteria 
was not associated with any missed or late-presenting cases 
of CMV retinitis in our HIV population. Indeed, since the 
introduction of the more stringent screening criteria (ie, from 
January 1, 2011, to the time of writing this paper), we have 
had no cases of HIV-associated CMV retinitis that would not 
have been picked up by these criteria.
Our adoption of a lower cutoff for asymptomatic patients 
is also supported by the large Longitudinal Study of Ocular 
Complications of AIDS (LSOCA).6 In this multicenter pro-
spective observational study, patients older than 13 years with 
a diagnosis of HIV were recruited from specialist ophthalmic 
clinics in the United States. The study was initiated in 1998, 
and as of December 31, 2009, it had enrolled 2,271 partici-
pants. Of these, 492 patients had CMV retinitis in at least 
one eye at enrollment. By looking at 1,600 patients who did 
not have CMV retinitis at baseline and who had 6 months 
or longer of follow-up, the investigators found 29 incident 
cases during 8,134 person-years of follow-up. This translates 
into an incidence rate of CMV retinitis in individuals with 
AIDS of 0.36/100 person-years. The investigators note that 
a CD4 count lower than 50 cells/mm3 was the single most 
important risk factor for the development of CMV retinitis, 
with a hazard ratio of 136 (95% confidence interval, 30–605) 
and an incidence rate of 3.89/100 person-years. 
The increased risk associated with a CD4 count lower 
than 50 cells/mm3 has been observed in a number of stud-
ies, including some from the pre-HAART era. In 1992, 
Pertel et al6 reported that based on Kaplan–Meier survival 
curves, the percentage of patients developing CMV retinitis 
by 27 months with baseline CD4 lymphocyte counts of 
0–50, 51–100, and 101–250 cells/mm3 was 41.9%, 26.3%, 
and 14.7%, respectively (log-rank test, P=0.003). In support 
of this, Lai et al report that patients with baseline CD4 cell 
count lower than 100 cells/mm3 were significantly associ-
ated with the presence of CMV retinitis (χ2-test, P=0.013).4 
Gharai et al reviewed 199 eyes in HIV-infected patients and 
found that the median CD4 count of the patients with active 
CMV retinitis was 75 cells/mm3.12
In our study, we noted that only one of seven patients with 
HIV-associated ophthalmic disease was receiving HAART 
before referral for ophthalmic screening. This was because 
most of the patients were newly diagnosed or had a known T
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diagnosis but were new to the United Kingdom; those cases 
who were not taking HAART before ophthalmic review 
were started on HAART by the HIV service immediately 
after ophthalmic review. Previous studies have observed 
improved prognosis in CMV retinitis patients receiving 
HAART, specifically in terms of reduced progression, 
detachment, and visual loss.11,13–15 In the LSOCA report 
by Sugar et al,7 the investigators comment that 26 of the 
29 patients with CMV retinitis and a CD4 count lower than 
50/cells/mm3 had been noted to have been receiving HAART 
at the clinic review immediately before the ophthalmic 
assessment, suggesting there was either treatment failure or 
lack of adherence.6 
It should be noted, however, that CMV retinitis may 
occur in patients with CD4 counts higher than 50 cells/mm3, 
and that our screening criteria would therefore miss these 
individuals. Jacobson et al10 reported five cases in whom the 
CD4 counts were higher than 195 cells/mm3 at the time of 
diagnosis of CMV retinitis. Of interest, however, is that all 
five cases had CD4 counts lower than 85 cells/mm3 at baseline 
(which was within the previous 6 months), and three of the 
five had CD4 counts lower than 50 cells/mm3. The LSOCA 
study noted one incident case of CMV retinitis with a CD4 
count in the 50–99 cells/mm3 range (incident rate, 0.18/100 
person-years) and two cases in the higher than 100 cells/mm3 
group (incident rate, 0.03/100 person-years).6 Again, it should 
be noted that these counts refer to the CD4 level at the visit 
immediately preceding their ophthalmic assessment and that 
all three cases had recorded levels lower than 50 cells/mm3 
at some earlier point in their disease. 
CMV retinitis is a blinding condition, and our patient with 
CMV retinitis lost her vision to hand movements despite treat-
ment with high dose intravenous and intravitreal ganciclovir. 
Intravitreal ganciclovir is a useful treatment for CMV retini-
tis, as it avoids the adverse effects and high doses from low 
bioavailability of systemic treatment.16 However, treatment 
requires monthly appointments and close follow-up in a group 
of patients at high risk for nonattendance. Appropriate screen-
ing and early detection are therefore of upmost importance.
There was a significant increase in the African/Afro-
Caribbean population between the first and second screen-
ing periods, reflecting overall changes in the Birmingham 
population. Census data show that although during the last 
decade the proportion of people in Birmingham identifying 
themselves as Afro-Caribbean has fallen slightly, going from 
4.9% to 4.5% (2001 versus 2011 Census data), the proportion 
of people identifying themselves as African has increased 
from 0.6% to 2.8%.17 This could be as a result of a number 
of factors. A recent study across 1,111 countries evalu-
ated the role of poverty in racial/ethnic disparities in HIV 
 prevalence.18 It found that racial/ethnic disparities remained 
in nonurban areas, but there was not a significant difference 
in urban areas when controlled for poverty.18
We recognize that even though our study was conducted 
within a large urban population (all of South Birmingham, 
United Kingdom), the actual cohort is relatively small and 
cannot be used to provide incident data in line with the 
LSOCA study. This is, of course, to be welcomed, as it 
reflects the dramatic health improvement in the HIV popula-
tion since the advent of HAART. As CMV retinitis becomes 
less common, accurate estimates for its incidence and 
prevalence in the United Kingdom will depend on national 
surveys (such as conducted through the British Ophthalmic 
Surveillance Unit), networks, or the establishment of a 
national registry for such cases. This last option would also 
provide the opportunity for prospective standardized capture 
of data similar to that adopted by the LSOCA, in contrast to 
the retrospective nature of ours and most other studies.
CMV retinitis is a potentially avoidable, blinding condi-
tion. Patients with low CD4 counts are often asymptomatic. 
Our data support the findings of other studies: that in patients 
taking HAART, CMV retinitis is increasingly rare, and 
when it does occur, it is usually in patients with a CD4 cell 
count lower than 50 cells/mm3. Given the low frequency of 
CMV retinitis and the cost of screening, it may be argued 
that ophthalmic screening of asymptomatic HIV patients is 
not necessary. We would argue that the devastating effect 
of CMV retinitis, its rapid asymptomatic progression, and 
the availability of effective treatment sufficiently justify 
screening in the highest-risk groups. On the basis of studies 
such as the LSOCA,6 and supported by our local experi-
ence, we argue that a CD4 count lower than 100 cells/mm3 
is a reasonable threshold to use for screening asymptomatic 
patients with known HIV.
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